Morphosys

from Wikipedia, the free encyclopedia
MorphoSys AG

logo
legal form Corporation
ISIN DE0006632003
founding 1992
Seat Planegg , GermanyGermanyGermany 
management
  • Jean-Paul Kress, CEO
  • Jens Holstein Chief Financial Officer
  • Malte Peters, Board Member for Research and Development
  • Roland Wandeler, Chief Commercial Officer
Number of employees 426 (2019)
sales 71.8 million euros (2019)
Branch biotechnology
Website www.morphosys.de
As of May 5, 2020

The MorphoSys AG is a 1992 based biopharmaceutical company with headquarters in Planegg near Munich . The company has a wholly-owned subsidiary in Boston , USA. The company has various antibody , protein and peptide technologies that it uses to research and develop both its own and partnered drug candidates. The company says it has more than 100 drugs in its pipeline that are being studied for the treatment of a wide variety of diseases. While many of these are developed in partnerships with pharmaceutical and biotech companies, Morphosys also has its own pipeline focused on cancer .

The company's share is part of the MDAX and TecDAX and is listed on the Frankfurt Stock Exchange and on the US NASDAQ stock exchange.

Business area

Morphosys’s main technology is an antibody library called HuCAL ® , which is used by scientists to produce human antibodies. This collection includes more than ten billion different human antibodies in the form of a phage display bank. Morphosys makes the HuCAL ® library available to several partner companies in return for license fees, either for the development of therapeutic agents based on monoclonal antibodies or for research purposes.

Morphosys also receives milestone payments in the drug development partnerships for the achievement of certain development goals (e.g. delivery of an antibody against a given target molecule, start of clinical testing with a HuCAL ® antibody, approval as a drug). These milestone payments add up to a total of around 10 million US dollars per active ingredient project. The more advanced a project is in development, the higher the individual payments are usually. Morphosys also receives a share of the sales of finished drugs from the projects.

Morphosy's partner companies include the following international pharmaceutical groups:

In January 2005, Morphosys acquired the British Biogenesis group for £ 5.25 million (around EUR 6.3 million). In January 2006, Morphosys acquired the British Serotec group for GBP 20 million (around EUR 24 million). With the merger of the two brands into AbD Serotec, Morphosys claims to have become the largest provider of antibodies for research in Europe. In December 2012, the Californian biotechnology company Bio-Rad Laboratories took over the research and diagnostics division AbD Serotec against payment of 48 million euros plus a license payment for the use of HuCAL® technology. In October 2010 Morphosys took over the Puchheim- based private Sloning Biotechnologie GmbH for 19 million euros. In May 2015, Morphosys took over the Dutch company Lanthio Pharma BV. Lanthio was the first company in which Morphosys had previously acquired equity. As part of a Series A financing round, Morphosys acquired around 20% of Lanthio in 2012.

Currently, no drug based on HuCAL® technology has been developed to market maturity.

Pipeline & Clinical Studies

As of December 2019, Morphosys had 116 drug candidates (twelve proprietary and 104 partnered programs), 28 of which were in clinical development.

Tafasitamab (MOR208) is a humanized monoclonal antibody against CD19 that is in clinical development for the treatment of B-cell malignancies. Tafasitamab is or has been tested in several clinical studies alone and in combination with other cancer drugs.

A total of six of its own drugs and over 65 by partner companies are currently being developed on the basis of HuCAL technology.

technology

Morphosys has developed a number of antibody technologies that it uses in both its proprietary and partner programs.

Morphosys' main technology is HuCAL (Human Combinatorial Antibody Library), a collection of more than ten billion fully human antibodies in the form of a phage display database and a system for optimizing them.

Business figures

Multi-year comparison
year 2012 2013 2014 2015 2016 2017 2018 2019
Turnover (million euros) 64.9 78.0 64.0 106.2 49.7 66.8 76.4 71.8
Group result (million euros) 1.9 13.3 −3.0 17.2 −59.9 −67.6 −59.1 −107.9
Employees at the end of the year (number) 421 299 329 365 345 326 329 426

Web links

Individual evidence

  1. ↑ a b c d e f g h Annual Report 2019. (PDF) In: morphosys.de. Retrieved May 25, 2020 .
  2. ↑ MorphoSys US Inc. July 24, 2018, accessed May 7, 2020 .
  3. ↑ pipeline. In: morphosys.de. October 9, 2014, accessed May 7, 2020 .
  4. ↑ a b c 20-F 2019. In: sec.gov. Retrieved May 7, 2020 .
  5. ↑ Bio-Rad takes over AbD Serotec. (No longer available online.) Archived from the original on January 9, 2013 ; Retrieved January 10, 2013 .
  6. ↑ BIOCOM AG: Transcript: Morphosys buys Lanthio. (No longer available online.) Archived from the original on September 29, 2015 ; accessed on September 28, 2015 .
  7. ↑ In-house antibodies. In: morphosys.de. Retrieved May 8, 2020 .
  8. ↑ a b MOR208 (tafasitamab). In: morphosys.de. Retrieved May 8, 2020 .
  9. ↑ Antibody pipeline: overview. (No longer available online.) Archived from the original on June 6, 2010 ; Retrieved May 20, 2010 .
  10. ↑ HuCaL . MorphoSys.
  11. ↑ a b c MorphoSys AG: Annual Report 2014. (PDF) Accessed December 30, 2015 .
  12. ↑ MorphoSys AG: Annual Report 2015. (PDF) Accessed April 8, 2016 .
  13. ↑ Annual Report 2016. (PDF pfd) Morphosys AG, accessed on November 15, 2018 .
  14. ↑ Annual Report 2017 (PDF) MorphoSys AG, accessed on November 15, 2018 .